The nuclear export protein XPO1—from biology to targeted therapy

AS Azmi, MH Uddin, RM Mohammad - Nature reviews Clinical oncology, 2021 - nature.com
Abstract Exportin 1 (XPO1), also known as chromosome region maintenance protein 1,
plays a crucial role in maintaining cellular homeostasis via the regulated export of a range of …

[HTML][HTML] Broad targeting of resistance to apoptosis in cancer

RM Mohammad, I Muqbil, L Lowe, C Yedjou… - Seminars in cancer …, 2015 - Elsevier
Apoptosis or programmed cell death is natural way of removing aged cells from the body.
Most of the anti-cancer therapies trigger apoptosis induction and related cell death networks …

Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): a …

S Grosicki, M Simonova, I Spicka, L Pour, I Kriachok… - The Lancet, 2020 - thelancet.com
Background Selinexor combined with dexamethasone has shown activity in patients with
heavily pre-treated multiple myeloma. In a phase 1b/2 study, the combination of oral …

[HTML][HTML] Oral selinexor–dexamethasone for triple-class refractory multiple myeloma

A Chari, DT Vogl, M Gavriatopoulou… - … England Journal of …, 2019 - Mass Medical Soc
Background Selinexor, a selective inhibitor of nuclear export compound that blocks exportin
1 (XPO1) and forces nuclear accumulation and activation of tumor suppressor proteins …

[HTML][HTML] Management of relapsed and refractory multiple myeloma: novel agents, antibodies, immunotherapies and beyond

CS Chim, SK Kumar, RZ Orlowski, G Cook… - Leukemia, 2018 - nature.com
Despite enormous advances, management of multiple myeloma (MM) remains challenging.
Multiple factors impact the decision to treat or which regimen to use at MM …

Genomic and molecular characterization of esophageal squamous cell carcinoma

DC Lin, JJ Hao, Y Nagata, L Xu, L Shang, X Meng… - Nature …, 2014 - nature.com
Esophageal squamous cell carcinoma (ESCC) is prevalent worldwide and particularly
common in certain regions of Asia. Here we report the whole-exome or targeted deep …

[HTML][HTML] XPO1-dependent nuclear export as a target for cancer therapy

NG Azizian, Y Li - Journal of hematology & oncology, 2020 - Springer
Cellular homeostasis requires the proper nuclear-cytoplasmic partitioning of large
molecules, which is often deregulated in cancer. XPO1 is an export receptor responsible for …

APRIL and BCMA promote human multiple myeloma growth and immunosuppression in the bone marrow microenvironment

YT Tai, C Acharya, G An, M Moschetta… - Blood, The Journal …, 2016 - ashpublications.org
Here we show that overexpression or activation of B-cell maturation antigen (BCMA) by its
ligand, a proliferation-inducing ligand (APRIL), promotes human multiple myeloma (MM) …

Novel anti–B-cell maturation antigen antibody-drug conjugate (GSK2857916) selectively induces killing of multiple myeloma

YT Tai, PA Mayes, C Acharya, MY Zhong… - Blood, The Journal …, 2014 - ashpublications.org
B-cell maturation antigen (BCMA), highly expressed on malignant plasma cells in human
multiple myeloma (MM), has not been effectively targeted with therapeutic monoclonal …

[HTML][HTML] Nucleo-cytoplasmic transport as a therapeutic target of cancer

GL Gravina, W Senapedis, D McCauley… - Journal of hematology & …, 2014 - Springer
Shuttling of specific proteins out of the nucleus is essential for the regulation of the cell cycle
and proliferation of both normal and malignant tissues. Dysregulation of this fundamental …